Security record · archived quarter
ARVN
Arvinas, Inc. · Healthcare · Biotechnology
10Tracked holders
n/aΔ holders
10.17MShares held
$270.82MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 78.53K | $605,140 | n/a | n/a |
| Q2 2026 | 82 | -2 | 34.83M | $289.66M | +6 | −8 |
| Q1 2026 | 87 | +4 | 31.95M | $338.79M | +7 | −3 |
| Q4 2025 | 83 | +1 | 38.40M | $455.50M | +2 | −1 |
| Q3 2025 | 15 | 0 | 28.59M | $243.63M | n/a | −1 |
| Q2 2025 | 13 | -1 | 30.77M | $226.45M | +1 | −2 |
| Q1 2025 | 11 | +1 | 13.86M | $97.33M | +1 | n/a |
| Q4 2024 | 10 | -1 | 12.65M | $242.44M | n/a | −1 |
| Q3 2024 | 10 | 0 | 10.38M | $255.76M | n/a | n/a |
| Q2 2024 | 10 | n/a | 10.17M | $270.82M | n/a | n/a |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 3.99M | n/a | $106.19M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Citadel Advisors ✦ | 2.64M | n/a | $70.26M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 1.54M | n/a | $41.05M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 1.08M | n/a | $28.70M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 275.40K | n/a | $7.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 224.35K | n/a | $5.97M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 200.20K | n/a | $5.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 178.33K | n/a | $4.75M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 26.46K | n/a | $704,340 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | Marshall Wace ✦ | 20.20K | n/a | $537,724 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 205 holders, 53.97M shares, $548.70M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API